Epigenomics confident of achieving FY05 guidance despite Q3 revenue loss
This article was originally published in Clinica
In spite of its success at costs control, German molecular diagnostics company Epigenomics saw its third-quarter 2005 top-line fall 28% to Euro2.1m ($2.5m) from last year's level. The firm also widened its net loss for the period by 6% to Euro2.8m.
You may also be interested in...
Pfizer has launched its Ruxience rituximab biosimilar in the US at a 24% discount to the wholesale acquisition cost of the Rituxan original. The firm has also revealed that when it launches its Trazimera trastuzumab biosimilar in mid-February, it will be at a 22% discount to the Herceptin brand’s WAC.
A patent-litigation settlement that Teva has reached with Ironwood and Allergan over Linzess will allow the Israeli firm to enter the US market with the linaclotide-based constipation treatment ahead of major rivals Mylan, Sandoz, Sun Pharma and Aurobindo.